|
|
Volumn 2, Issue 3, 2003, Pages 189-190
|
|
Gleevec resistance: lessons for target-directed drug development.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
IMATINIB;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
BINDING SITE;
CHRONIC MYELOID LEUKEMIA;
DRUG ANTAGONISM;
DRUG DESIGN;
DRUG EFFECT;
DRUG RESISTANCE;
GENETICS;
HUMAN;
METABOLISM;
PROTEIN TERTIARY STRUCTURE;
REVIEW;
TREATMENT FAILURE;
ANTINEOPLASTIC AGENTS;
BINDING SITES;
DRUG DESIGN;
DRUG RESISTANCE, NEOPLASM;
FUSION PROTEINS, BCR-ABL;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
PIPERAZINES;
PROTEIN STRUCTURE, TERTIARY;
PYRIMIDINES;
TREATMENT FAILURE;
MLCS;
MLOWN;
|
|
EID: 0141723426
PISSN: 15384101
EISSN: None
Source Type: Journal
DOI: 10.4161/cc.2.3.401 Document Type: Review |
|
Times cited : (13)
|
|
References (10)
|
